Compare
Side by side
Pick up to three peptides to see how their mechanisms, studied uses and evidence levels differ. Rows where the entries disagree are marked with a blue edge.
Selected 1 of 3
Comparison
Pinealon
Cognitive & neuro
Evidence level
Anecdotal evidence
Approval status
Not approved
Mechanism of action
- 1.Proposed to enter cells and bind DNA to influence gene expression — a hypothesis, not an established mechanism.
- 2.Russian-language animal work reports antioxidant and neuroprotective effects in brain tissue.
- 3.Reported effects on melatonin and sleep are speculative; there are no human pharmacokinetic data.
- 4.Short peptides are rapidly broken down by blood enzymes, which raises the question of how an injected dose reaches the brain.
- 5.Crossing the blood-brain barrier at this size is unproven.
Studied for
- Age-related cognitive decline (Russian animal and small clinical reports)
- Sleep quality and pineal function
- Neuroprotection after experimental injury
- No independent replication exists in Western literature
Reported effects
- Reported memory-test improvements in small, poorly controlled Russian studies
- Reported better sleep in user accounts
- No verified human effect
- Antioxidant markers changed in animal work
Side effects
- Not systematically studied
- Reported: headache, drowsiness, irritability
- Injection-site reactions
- Long-term safety completely unknown
Research protocol
Research context only — there is no approved protocol. Vendor material describes 10 mg vials reconstituted in 1 ml of bacteriostatic water with 10–20 syringe units daily for around 20 days; those figures come from supplier leaflets rather than trials, and the unit count means nothing without an exact concentration.
Research context only
Evidence justification
There are no peer-reviewed controlled trials in humans; available evidence is limited to Russian-language reports and user accounts that cannot be independently verified.